Tofisopam

Overview

Tofisopam is chemically a 2,3-benzodiazepine marketed as an anxiolytic under trade names including Emandaxin and Grandaxin. Unlike other anxiolytic benzodiazepines, which are generally 1,4- or 1,5-substituted, tofisopam does not have anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing or amnestic properties.[1–4] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

Pharmacology

Pharmacokinetics

Tofisopam is also claimed to be a PDE10A inhibitor, which may provide an alternative mechanism of action for its various therapeutic effects, and this action has been proposed to make tofisopam potentially useful as a treatment for schizophrenia.[5] WP

Tofisopam has been shown to act as an inhibitor of the liver enzyme CYP3A4, and some researches suspect that this could cause dangerous drug interactions with other medications metabolised by this enzyme, although the clinical significance of these findings remains unclear.[6–9] WP

Chemistry

Formula

C22H26N2O4 PC

CAS number

22345-47-7 PC

Molar mass (g/mol)

382.5 PC

IUPAC name (computed by PubChem)

1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine PC

SMILES

CCC1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C PC

InChIKey

RUJBDQSFYCKFAA-UHFFFAOYSA-N PC

PubChem CID

5502

IUPAC name

1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other DE Patent 2122070
2. Other Index Nominum 2000: International Drug Directory. January 2000
3. Journal / agency Bond A, Lader M. A comparison of the psychotropic profiles of tofisopam and diazepam. European Journal of Clinical Pharmacology. 1982. doi:10.1007/BF00542458 · PMID 6124424
4. Journal / agency Seppälä T, Palva E, Mattila MJ, Korttila K, Shrotriya RC. Tofisopam, a novel 3,4-benzodiazepine: multiple-dose effects on psychomotor skills and memory. Comparison with diazepam and interactions with ethanol. Psychopharmacology. 1980. doi:10.1007/BF00427652 · PMID 6109345
5. Other Nielsen EB, Kehler J, Nielsen J, Brøsen P. Use of Tofisopam as a PDE10A inhibitor. WIPO Patent WO/2007/082546
6. Journal / agency Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. FDA. May 26, 2021
7. Journal / agency Tóth M, Bajnógel J, Egyed A, Drabant S, Tömlo J, Klebovich I. Effect of tofisopam on CYP3A4 enzyme activity on human recombinant 3A4 supersome. Acta Pharmaceutica Hungarica. 2005. PMID 16711396
8. Journal / agency Drabant S, Tóth M, Bereczki A, Bajnógel J, Tömlö J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. European Journal of Clinical Pharmacology. July 2006. doi:10.1007/s00228-006-0160-9 · PMID 16791582
9. Journal / agency Tóth M, Drabant S, Varga B, Végso G, Cseh A, Szentpéteri I, Klebovich I. Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam. European Journal of Clinical Pharmacology. January 2008. doi:10.1007/s00228-007-0397-y · PMID 17989974

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.